NXL

Nexalin Technology, Inc. (NXL) - Q1 2025 Filing Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended March 31, 2025. Nexalin Technology, Inc. is a medical device company developing non-invasive neurostimulation products (Gen-1, Gen-2 "SYNC", and Gen-3 "HALO") to treat anxiety, insomnia, and depression. The company is classified as a Smaller Reporting Company and an Emerging Growth Company. While Gen-1 devices are restricted in the U.S. due to FDA reclassification, the company continues to derive revenue from legacy licensing and supplies. Newer Gen-2 and Gen-3 devices are in various stages of FDA pre-submission and clinical trial planning, with Gen-2 approved for use in China and Brazil.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: Net revenue decreased by 48% to $41,015, primarily due to the absence of device sales to a new overseas customer that occurred in Q1 2024. Revenue is now driven by licensing fees and equipment sales (electrodes/cables), which have lower margins.
• Increased Operating Expenses: Total operating expenses rose 78% to $2.04 million. Key drivers include:
  • R&D: Increased 284% to $406,288 due to development of Gen-2 and Gen-3 devices.
  • SG&A: Increased 92% to $929,220, driven by higher professional fees (investor relations) and consulting costs.
  • Stock Compensation: Increased significantly to $636,844 (up from $161,349) due to grants to consultants and executives.
• Liquidity Position: Short-term investments decreased by approximately $1.48 million as the company sold investments to fund operations, though cash and cash equivalents increased slightly to $622,029.
• Accumulated Deficit: The accumulated deficit grew to approximately $86.6 million.

Outlook, Risks, and Contingencies

• Going Concern: The filing states that substantial doubt exists regarding the company's ability to continue as a going concern within one year without additional capital. Management believes a public offering consummated on May 6, 2025 (raising ~$5 million), provides sufficient liquidity for the next 12 months.
• Regulatory Pathway: The company is in the Q-submission process with the FDA for Gen-2 (SYNC) and Gen-3 (HALO). Gen-1 marketing for new sales in the U.S. is paused pending FDA approval for anxiety and insomnia indications. Gen-2 is approved in China and Brazil.
• Nasdaq Compliance: The company has faced repeated notices regarding the Minimum Bid Price Rule ($1.00) and Minimum Stockholder Equity Rule ($2.5 million). It regained compliance with the bid price rule in October 2024 and the equity rule in July 2024 following a capital raise.
• Legal Proceedings:
  • Sarah Veltz v. Nexalin: A lawsuit regarding unpaid wages and sexual harassment was settled in May 2025 for a confidential amount. Management expects no material financial impact.
  • EDD Dispute: The company is in settlement discussions with the California Employment Development Department regarding worker classification. A liability of $40,000 has been accrued.
• Internal Controls: Management identified material weaknesses in internal controls over financial reporting, specifically regarding segregation of duties and IT controls. Disclosure controls were deemed ineffective as of March 31, 2025.

Investor Verification Checklist

• Cash Runway: Verify the actual proceeds and net cash impact of the May 6, 2025 public offering to confirm the 12-month liquidity assertion.
• Revenue Concentration: Note that two customers accounted for 50% of Q1 2025 revenue; monitor the stability of these relationships.
• FDA Milestones: Track the status of the Q-submission feedback for Gen-2 and Gen-3 devices, as commercialization depends entirely on FDA clearance.
• Stock Compensation: Review the impact of the $636k stock compensation expense on future dilution and cash burn.
• Internal Control Remediation: Monitor progress on fixing the material weaknesses in financial reporting controls to ensure future filing reliability.